RT Journal Article
SR Electronic
T1 Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.01.22277143
DO 10.1101/2022.07.01.22277143
A1 Geisen, Ulf Martin
A1 Rose, Ruben
A1 Neumann, Franziska
A1 Ciripoi, Maria
A1 Vullriede, Lena
A1 Reid, Hayley M
A1 Berner, Dennis Kristopher
A1 Bertoglio, Federico
A1 Hoff, Paula
A1 Hust, Michael
A1 Longardt, Ann Carolin
A1 Lorentz, Thomas
A1 Rios Martini, Gabriela
A1 Saggau, Carina
A1 Schirmer, Jan Henrik
A1 Schubert, Maren
A1 Sümbül, Melike
A1 Tran, Florian
A1 Voß, Mathias
A1 Zeuner, Rainald
A1 Morrison, Peter J
A1 Bacher, Petra
A1 Fickenscher, Helmut
A1 Gerdes, Sascha
A1 Peipp, Matthias
A1 Schreiber, Stefan
A1 Krumbholz, Andi
A1 Hoyer, Bimba Franziska
YR 2022
UL http://medrxiv.org/content/early/2022/07/03/2022.07.01.22277143.abstract
AB Objectives The humoral immune response to SARS-CoV-2 vaccination in patients with chronic inflammatory disease (CID) declines more rapidly with TNFα inhibition. Furthermore, the efficacy of current vaccines against Omicron variants of concern (VOC) including BA.2 is limited. Alterations within immune cell populations, changes in IgG affinity and the ability to neutralise a pre-VOC strain and the BA.2 virus were investigated in these at-risk patients.Methods Serum levels of anti-SARS-CoV-2 IgG, IgG avidity and neutralising antibodies (NA) were determined in anti-TNFα patients (n=10) and controls (n=24 healthy individuals; n=12 patients under other disease-modifying anti-rheumatic drugs, oDMARD) before and after the second and third vaccination by ELISA, immunoblot and live virus neutralisation assay. SARS-CoV-2-specific B-and T cell subsets were analysed by multicolour flow cytometry.Results IgG avidity and anti-pre-VOC NA titres decreased faster in anti-TNFα recipients than in controls 6 months after the second vaccination (healthy individuals: avidity: p≤0.0001; NA: p=0.0347; oDMARDs: avidity: p=0.0012; NA: p=0.0293). Total plasma cell counts were increased in anti-TNFα patients (Healthy individuals: p=0.0344; oDMARDs: p=0.0254), whereas absolute numbers of SARS-CoV-2-specific cells were comparable 7 days after vaccination. These patients had lower BA.2 NA titres compared to both other groups, even after the third vaccination.Conclusions We show a reduced SARS-CoV-2 neutralising capacity in patients under TNFα blockade. In this cohort, the plasma cell response appears to be less specific and show stronger bystander activation. While these effects were observable after the first two vaccinations and with older VOC, the differences in responses to BA.2 were magnified.What is already known on this topic Patients with chronic inflammatory diseases treated with TNFα inhibitors show a greater decrease in SARS-CoV-2 IgG 6 months after the second vaccination than patients taking oDMARDs and healthy individuals.What this study adds Antibodies from patients taking TNFα blockers have a lower SARS-CoV-2 neutralising capacity and maturity. Plasma cells from these patients exhibit less specific immune reaction. SARS-CoV-2-specific T cells are less activated. Neutralisation against BA.2 is drastically reduced even after the third vaccination.How this study might affect research, practice or policy This study emphasizes the need to protect vulnerable groups such as patients using TNF inhibitors. They could benefit from Omicron-adapted vaccination, but most likely they need to be protected by additional means other than vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCross-funded by Bundesministerium für Bildung und Forschung (Grant GAIN_01GM1910D), DIO002/CoVispecT research grant from the Land Schleswig-Holstein, the German Network University Medicine NUM NaFoUniMedCovid19 (FKZ: 01KX2021), project COVIM and by the Deutsche Forschungs-Gemeinschaft Cluster of Excellence Precision Medicine in Chronic Inflammation and Transregio 130. BFH, PH and SS received funding from Pfizer and other companies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Kiel University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yesrt4 pqoI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors